After DEX treatment, the protein expressions of Rac1/AKT/NF-κB and proportion of NF-κB entering the nucleus markedly declined, indicating that DEX may exert a therapeutic effect on SD via the Rac1/AKT/NF-κB signaling pathway. This evidence concerns the gene NFKB1 and Salla disease.